Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 11/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.60 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.38 |
| ▸ | PDE2A | O00408 | 2/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22438830 | 0.96 | IDO1 (0.59) | IDO1CYP2C9HDAC3HDAC1HDAC2 | |
| SCHEMBL23908253 | 0.84 | IDO1 (0.45) | IDO1CYP2C9BTKHDAC3HDAC1 | |
| SCHEMBL23908266 | 0.84 | IDO1 (0.45) | IDO1CYP2C9BTKHDAC3HDAC1 | |
| SCHEMBL23908255 | 0.84 | IDO1 (0.45) | IDO1CYP2C9BTKHDAC3HDAC1 | |
| SCHEMBL22438913 | 0.83 | IDO1 (0.54) | IDO1CYP2C9HDAC3HDAC1HDAC2 | |
| SCHEMBL22439069 | 0.83 | IDO1 (0.42) | IDO1CYP2C9BTKHDAC3HDAC1 | |
| Trifluoroacetic Acid SCHEMBL30070605 | 0.81 | IDO1 (0.42) | IDO1CYP2C9BTKHDAC3HDAC1 | |
| SCHEMBL22439040 | 0.81 | IDO1 (0.66) | IDO1CYP2C9HDAC3HDAC1HDAC2 | |
| SCHEMBL22438775 | 0.80 | IDO1 (0.41) | IDO1CYP2C9BTKHDAC3HDAC1 | |
| SCHEMBL22438754 | 0.78 | FASN (0.43) | IDO1CYP2C9PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317091-A1 | NOVEL SUBSTITUTED BIARYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317091-A1 | NOVEL SUBSTITUTED BIARYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | IDO1, IDO2, KYNU | IDO1 1/4885CYP2C9 915/4885BTK 882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.